摘要
目的探讨泼尼松联合甲巯咪唑治疗Graves病的临床价值。方法选择86例Graves病患者,随机分为两组,观察组使用泼尼松片联合甲巯咪唑治疗,对照组单用甲巯咪唑治疗,比较两组患者治疗前后甲状腺体积和突眼程度,并分析治疗后两组患者白细胞亚群计数。结果治疗后观察组甲状腺体积小于对照组(P<0.05),同时突眼程度亦低于对照组(P<0.05),CD4和CD8水平均显著高于对照组(P<0.05),CD4/CD8高于对照组(P<0.05)。结论泼尼松联合甲巯咪唑治疗Graves病在保证临床治疗效果的同时,能有效地减少甲巯咪唑抑制白细胞的不良反应,更好地提高患者耐受性。
Objective To explore the clinical value of prednisone combined with methimazole for Graves disease. Methods 86 cases were divided into two groups, the observation group was given prednisone tablets combined with methimazole, while the control group was only given methimazole, then the thyroid volume and exophthalmos degree before and after treatment and leukocyte subsets were compared in the two groups. Results After treatment, the thyroid volume and exophthalmos degree of observation group were better than control group （P〈0.05）, CD4 and CD8 levels were higher than control group （P〈0.05）, CD4/CD8 was higher than control group （P〈0.05）. Conclusion Prednisone combined with methimazole can ensure the clinical treatment effect and reduce the adverse reaction of inhibit leuko-cyte by methimazole, so it can improve patients＇ tolerance.
出处
《中国当代医药》
2013年第25期70-71,共2页
China Modern Medicine
